Newer Trends in Use Sglt-2 in Diabeties Mellitus

Diabetes Mellitus (DM) is a widespread metabolic condition marked by persistent hyperglycemia, impacting millions globally. Conventional therapy methods possess constraints, highlighting the necessity for novel therapeutic solutions. Sodium-glucose cotransporter 2 (SGLT-2) inhibitors have emerged as a potential category of anti-diabetic medications, providing a transformative approach to diabetes management. This review explores contemporary trends in the utilization of SGLT-2 inhibitors, emphasizing their mechanisms, advantages, and prospective applications beyond glycemic regulation. We examine the function of SGLT-2 inhibitors in mitigating cardiovascular risk, safeguarding renal health, and managing weight, along with their prospective use in addressing other metabolic illnesses. Additionally, we examine the most recent studies about the application of SGLT2 inhibitors in combination therapy, their effectiveness in particular patient demographics, and the current clinical trials. This abstract offers a thorough examination of the present state of SGLT2 inhibitors in diabetes care, highlighting its future trajectories and potentialities.